市場調查報告書
商品編碼
1535248
EGFR檢驗市場:各市場區隔規模,佔有率,法律規章,償付,2033年為止的預測EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
表皮生長因子受體 (EGFR) 基因檢測用於檢測非小細胞肺癌腫瘤細胞中此受體基因的突變。這些結果可能會確定針對 EGFR 的酪胺酸激?抑制劑(例如吉非替尼和厄洛替尼)是否有益於治療非小細胞肺癌(NSCLC)。
EGFR是受體酪胺酸激?家族的成員,是調節細胞增生、侵襲、轉移、血管生成和抑制細胞凋亡的關鍵因子。 EGFR 是 NSCLC 中最常檢測的生物標記之一。腺癌中發現的大多數 EGFR 突變位於酪胺酸激?結構域。
本報告提供全球EGFR檢驗市場相關資料詳細考察,提供市場上競爭情形,SWOT分析,到2033年為止的市場預測,地區,各國的趨勢等資訊。
EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Epidermal Growth Factor Receptor gene (EGFR) Tests are carried out to detect mutations within this receptor gene in non-small cell lung cancer tumor cells. The outcome of which may determine if EGFR-targeted tyrosine kinase inhibitors such as gefitinib and erlotinib may be beneficial for treating non-small cell lung cancer (NSCLC).
EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating cellular proliferation, invasion, metastasis, angiogenesis, and inhibition of apoptosis. EGFR is one of the most routinely tested biomarkers in NSCLC.Most EGFR mutations found in adenocarcinoma are located in the tyrosine kinase domain.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed EGFR Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Roche Diagnostics International Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Agena Bioscience Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Panagene Inc and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -